Home LiteratureArticle Details
PMID: 24767767 Published · ppublish English Clinical Trial Journal Article Research Support, N.I.H., Extramural

Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.

The Lancet. Respiratory medicine ·Vol. 2 ·No. 7 ·2014-07-00 ·Pages 548-56

Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, Moore BB, White ES, Flaherty KR, Huffnagle GB, Martinez FJ, COMET Investigators

Abstract

The role of the lung microbiome in the pathogenesis of idiopathic pulmonary fibrosis is unknown. We investigated whether unique microbial signatures were associated with progression of idiopathic pulmonary fibrosis. Patients (aged 35-80 years) with idiopathic pulmonary fibrosis within 4 years of diagnosis from the Correlating Outcomes with biochemical Markers to Estimate Time-progression (COMET) in idiopathic pulmonary fibrosis study were followed up for a maximum of 80 weeks. Progression-free survival was defined as time to death, acute exacerbation, lung transplant, or decrease in forced vital capacity (FVC) of 10% or greater or decrease in diffusion capacity of the lung (DLCO) of 15% or greater. DNA was isolated from 55 samples of bronchoscopic alveolar lavage. 454 pyrosequencing was used to assign operational taxonomic units (OTUs) to bacteria based on a 3% sequence divergence. Adjusted Cox models were used to identify OTUs that were significantly associated with progression-free survival at a p<0.10. These OTUs were then used in the analysis of the principal components. The association between principal components and microbes with high factor loadings and progression-free survival were assessed with Cox regression analyses. The COMET study is registered with ClinicalTrials.gov, number NCT01071707. Mean FVC was 70.1% (SD 17.0) and DLCO 42.3% (14.0) of predicted. Disease progression was significantly associated with increased relative abundance of two OTUs-Streptococcus OTU 1345 (relative risk 1.11, 95% CI 1.04-1.18; p=0.0009) and Staphylococcus OTU 1348 (1.16, 1.03-1.31, p=0.012). Thresholds for relative abundance of each OTU associated with progression-free survival were more than 3.9% for Streptococcus OTU 1345 (10.19, 2.94-35.35; p=0.0002) and more than 1.8% for Staphylococcus OTU 1348 (5.06, 1.71-14.93; p=0.003). These preliminary data suggest progression of idiopathic pulmonary fibrosis is associated with the presence of specific members within the Staphylococcus and Streptococcus genera. Additional research will be needed to identify the specific bacterial species and to ascertain whether this is a causal association. National Institutes of Health.

MeSH Terms
Adult Aged Aged, 80 and over DNA, Bacterial Disease Progression Disease-Free Survival Female Follow-Up Studies Humans Idiopathic Pulmonary Fibrosis/microbiology,physiopathology Lung/microbiology Male Microbiota Middle Aged Sequence Analysis, DNA Staphylococcus/genetics,isolation & purification Streptococcus/genetics,isolation & purification Vital Capacity
Chemicals
DNA, Bacterial
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Han MeiLan K
University of Michigan Health System, Ann Arbor, MI, USA. Electronic address: mrking@umich.edu.
Zhou Yueren
University of Michigan Health System, Ann Arbor, MI, USA.
Murray Susan
University of Michigan Health System, Ann Arbor, MI, USA.
Tayob Nabihah
University of Michigan Health System, Ann Arbor, MI, USA.
Noth Imre
University of Chicago, Chicago, IL, USA.
Lama Vibha N
University of Michigan Health System, Ann Arbor, MI, USA.
Moore Bethany B
University of Michigan Health System, Ann Arbor, MI, USA.
White Eric S
University of Michigan Health System, Ann Arbor, MI, USA.
Flaherty Kevin R
University of Michigan Health System, Ann Arbor, MI, USA.
Huffnagle Gary B
University of Michigan Health System, Ann Arbor, MI, USA.
Martinez Fernando J
University of Michigan Health System, Ann Arbor, MI, USA.
COMET Investigators
Investigators
35 investigators, click to expand
Dushay Kevin
Kurtis Jonathon
Chapman Jeffrey T
Anstrom Kevin
Brown Kevin K
Cosgrove Gregory
Solomon Joshua
Swigris Jeffrey
Fernandez-Perez Evans
Criner Gerard
Cordova Francis
Patel Namrata
Rogers Thomas
Belperio John
King Talmadge E
Collard Harold R
Noth Imre
Brown Cathy
Garcia Joe G N
Hogarth D Kyle
Huang Yong
Lussier Yves
Ma Shwu-Fan
Wade Michael
Martinez Fernando J
Flaherty Kevin R
Toews Galen B
White Eric S
Hogaboam Cory
Lama Vibha
Moore Bethany
Moore Thomas
Murray Susan
Spino Cathie
Loyd James E
References (36)
36 references, click to expand
  1. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis.
    Am J Respir Crit Care Med. 2013 Dec 15;188(12):1442-50 PMID: 24070541
  2. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
    Eur Respir J. 2007 Nov;30(5):835-9 PMID: 17978154
  3. Significance of the microbiome in obstructive lung disease.
    Thorax. 2012 May;67(5):456-63 PMID: 22318161
  4. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis.
    PLoS One. 2010 Jan 29;5(1):e8959 PMID: 20126467
  5. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?
    Am J Respir Crit Care Med. 2007 May 15;175(10):1054-60 PMID: 17255566
  6. Sex differences in physiological progression of idiopathic pulmonary fibrosis.
    Eur Respir J. 2008 Jun;31(6):1183-8 PMID: 18321929
  7. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
    N Engl J Med. 2012 May 24;366(21):1968-77 PMID: 22607134
  8. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis.
    Sci Transl Med. 2010 Nov 10;2(57):57ra82 PMID: 21068441
  9. Analysis of the lung microbiome in the "healthy" smoker and in COPD.
    PLoS One. 2011 Feb 22;6(2):e16384 PMID: 21364979
  10. Microbial communities in the respiratory tract of patients with interstitial lung disease.
    Thorax. 2013 Dec;68(12):1150-6 PMID: 23945167
  11. Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis.
    Thorax. 2009 Aug;64(8):692-7 PMID: 19359270
  12. Comparison of the respiratory microbiome in healthy nonsmokers and smokers.
    Am J Respir Crit Care Med. 2013 May 15;187(10):1067-75 PMID: 23491408
  13. Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus.
    Am J Respir Crit Care Med. 2008 Apr 1;177(7):771-80 PMID: 18187693
  14. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations.
    OMICS. 2010 Feb;14(1):9-59 PMID: 20141328
  15. Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy.
    Infect Immun. 2012 Oct;80(10):3371-80 PMID: 22778094
  16. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.
    Thorax. 2013 Feb;68(2):155-62 PMID: 23143842
  17. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis.
    Sci Transl Med. 2013 Oct 2;5(205):205ra136 PMID: 24089408
  18. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.
    Am J Respir Crit Care Med. 2012 May 15;185(10):1044-8 PMID: 22505745
  19. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.
    Nat Genet. 2013 Jun;45(6):613-20 PMID: 23583980
  20. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?
    Am J Respir Crit Care Med. 2004 Oct 15;170(8):904-10 PMID: 15256390
  21. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis.
    Eur Respir Rev. 2013 Sep 1;22(129):376-81 PMID: 23997064
  22. Acute exacerbations of idiopathic pulmonary fibrosis.
    Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43 PMID: 17585107
  23. High-throughput sequencing of PCR products tagged with universal primers using 454 life sciences systems.
    Curr Protoc Mol Biol. 2011 Oct;Chapter 7:Unit7.5 PMID: 21987058
  24. Evaluation of 16S rDNA-based community profiling for human microbiome research.
    PLoS One. 2012;7(6):e39315 PMID: 22720093
  25. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis.
    Eur Respir J. 2006 Jan;27(1):136-42 PMID: 16387946
  26. Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9.
    J Immunol. 2012 Oct 15;189(8):4040-6 PMID: 22962685
  27. Adaptive index models for marker-based risk stratification.
    Biostatistics. 2011 Jan;12(1):68-86 PMID: 20663850
  28. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis.
    Am J Respir Crit Care Med. 2011 Jun 15;183(12):1698-702 PMID: 21471095
  29. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis.
    Am J Physiol Lung Cell Mol Physiol. 2012 Dec 15;303(12):L1046-56 PMID: 23043074
  30. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
    Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824 PMID: 21471066
  31. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis.
    Am J Respir Crit Care Med. 2009 Jul 15;180(2):167-75 PMID: 19363140
  32. Disordered microbial communities in asthmatic airways.
    PLoS One. 2010 Jan 05;5(1):e8578 PMID: 20052417
  33. A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease.
    Pulm Pharmacol Ther. 2008;21(1):178-87 PMID: 17500020
  34. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.
    JAMA. 2013 Jun 5;309(21):2232-9 PMID: 23695349
  35. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study.
    Lancet Respir Med. 2013 Jun;1(4):309-317 PMID: 24429156
  36. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.
    PLoS Med. 2008 Apr 29;5(4):e93 PMID: 18447576
Article Info
Journal
The Lancet. Respiratory medicine
Abbr.
Lancet Respir Med
ISSN
2213-2619
Published
2014-07-00
Epub
2014-00-21
Pages
548-56
Language
English
Region
England
NLM ID
101605555
PMCID
PMC4142525
Subset
IM
Grants
NHLBI NIH HHS · K23 HL093351 · United States
NHLBI NIH HHS · R01 HL109118 · United States
NHLBI NIH HHS · R01 HL115618 · United States
NHLBI NIH HHS · RC2 HL101740 · United States
Databases
ClinicalTrials.gov
NCT01071707
Corrections
ErratumIn
-
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com